Important position in the value chain
The company has a meaningful role across upstream technology, downstream adoption or category infrastructure.
Find China’s healthcare assets worth your next conversation.
VCBeat does not sell static data. We package research conclusions: a curated view of high-quality Chinese healthcare assets, updated as companies evolve across financing, approvals, partnerships and market entry.
00 / Vertical Industries
01 / Selection standard
High-quality Chinese assets are selected by research judgement, not by raw volume.
Company data changes with stage, financing, product progress and BD momentum. VCBeat treats the map as a living research product, refreshed around a semiannual cycle rather than frozen as a one-time export.
Financing signal
Institutional financing helps confirm market attention, execution capacity and the company’s development stage.
Approved product progress
Products approved in China or global markets are tracked as concrete evidence of regulatory and commercial readiness.
BD cooperation with MNCs
Collaboration with multinational companies is treated as a key market validation signal, especially for overseas teams.
02 / Research edge
Our advantage is access to the companies behind the signal.
VCBeat has built deep coverage across the healthcare, pharmaceutical and medical-device sectors through long-term research, field interviews and market observation.
The team has interviewed a large share of companies in the covered tracks and maintains ongoing interaction with founding teams. For overseas pharma, device, investment and strategy teams, this creates a more useful view than a company list alone.
If you are exploring cooperation with companies in a specific track, VCBeat can also help you understand the right targets and open a more informed conversation.
“The value is not more rows. The value is knowing which Chinese assets deserve attention now.”
VCBeat research principle for overseas paid-content subscribers03 / Built for
Made for teams that need to evaluate, partner with or invest in China healthcare assets.
Pharma and biotech BD teams
Screen emerging Chinese companies by product progress, partnership relevance and collaboration readiness.
Medical-device companies
Understand category structure, upstream and downstream positions, and companies with approved market traction.
Investors and analysts
Track financing, listing status, milestones and news in context instead of reading disconnected updates.
04 / Complete data view
The map covers the core dimensions needed to evaluate each company.
Subscribers unlock a structured view that combines industry analysis, company-level detail and current market signals. The content is continuously iterated as new financing, approvals, BD events and news emerge.
Industry analysis
Market structure, category logic and research conclusions for the covered track.
Industry composition
Company clusters and the upstream-downstream structure behind the sector.
Company profiles
Business architecture, registration information and company development details.
BD intelligence
Relevant partnership, cooperation and multinational-company activity.
Latest news
Ongoing tracking of updates that change how a company should be evaluated.
Financing history
Funding rounds and investor signals viewed against the company’s stage.
Milestone events
Product, regulatory, commercial and partnership events that indicate progress.
Listing status
Public-market status tracking for companies that have reached or approached listing.
05 / Subscription access
Subscribe now to unlock the complete asset view.
The VCBeat map gives overseas teams a continuously updated view of Chinese healthcare companies: business registration data, business architecture, news tracking, financing history, listing status and research context in one place.
Contact VCBeat for access
Use this page for purchase introduction, subscriber onboarding and overseas BD or investment conversations.